drugset / Trial / NCT00298636

Dose-Response of Adenosine for Perioperative Pain

NCT00298636

Phase 2 Completed 160 enrolled Xsira Pharmaceuticals
RandomizedSingle-groupDouble-blindTreatment

Summary

Adenosine A1 and A2 receptors are widely distributed in the brain and spinal cord and represent a non-opiate target for pain management. Activated spinal A1 receptors inhibit sensory transmission by inhibiting the slow ventral root potential, which is the C-fiber-evoked excitatory response associated with nociception. Adenosine may inhibit intrinsic neurons through an increase in K+ conductance and presynaptic inhibition of sensory nerve terminals to inhibit the release of substance P and perhaps glutamate. Although adenosine A3 receptors are not found in the nervous system, adenosine is also known to have anti-inflammatory properties that may contribute to pain relief in the peripheral setting of inflammation.

Timeline

Start
2005-10
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Adenosine Small molecule Intravenous

Indications

No indication recorded.